Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Q1 2024 Earnings Presentation
15 slides from Zealand Pharma A/s's earnings presentation, May 16, 2024
Slide 1: Q1 2024 Presentation
Q1 2024 Presentation Zealand Pharma May 16, 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Solid start to 2024 with strong progress across obesity pipeline and PDUFA dates for rare disease assets
Solid start to 2024 with strong progress across obesity pipeline and PDUFA dates for rare disease assets Advancing differentiated obesity pipeline Progressing rare disease assets to patients Dasiglucagon in Petrelintide congenital hyperinsulinism • 16-week trial completed; on track amylin analog • P
Slide 4: We are well on track to deliver on the most important priorities for the year 2024
We are well on track to deliver on the most important priorities for the year 2024 Petrelintide Dapiglutide Survodutide2 (amylin analog) (GLP-1R/GLP-2R) (GCGR/GLP-1R) Ph1b 16-week MAD clinical trial Ph2a DREAM clinical trial data1 data Ph2 MASH clinical trial data Ph2b trial initiation Ph1b 13-week
Slide 5: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product candidatea Partnered Pre-clinical Phase 1 Phase 2 Phase 3 Registration , Dapiglutide (GLP-1R/GLP-2R dual agonist) Obesity Obesity Petrelintide (amylin analog) Obesity ZP6590 (GIP receptor agonist) Obesity Survodu
Slide 6: In late Q2 2024, we expect topline results with petrelintide from the Phase 1b 16-week trial
In late Q2 2024, we expect topline results with petrelintide from the Phase 1b 16-week trial The 16-week trial is exploring significantly higher A potentially best-in-class amylin analog doses using an up-titration scheme1 Targeting GLP-1RA-like weight reduction; high Trial design quality weight los
Slide 7: In mid-Q2 2024, we expect topline results with dapiglutide from the investigator-led trial DREAM
In mid-Q2 2024, we expect topline results with dapiglutide from the investigator-led trial DREAM DREAM evaluating effects on body weight, A first-in-class GLP-1R/GLP-2R dual agonist gut permeability and inflammation1 Safety and tolerability similar to other GLP- Trial design 1RA-based weight-loss me
Slide 8: Survodutide shows best-in-class potential in MASH Phase 2 trial
Survodutide* glucagon/GLP-1 receptor dual agonist shows best-in-class potential in MASH Phase 2 trial Phase 2 trial in people with overweight or obesity1 Phase 2 biopsy-driven trial in people with MASH3 Mean relative change at Week 46 (%) Participants showing improvement in MASH Adjusted mean (95% C
Slide 9: Dasiglucagon is being developed to address a high unmet medical need for the management of CHI
Dasiglucagon is being developed to address a high unmet medical need for the management of CHI US FDA has accepted the resubmission1 of NDA Part 1 with a PDUFA goal date of October 8, 2024 Two Phase 3 trials in neonates and children up to 12 years of age demonstrated clinical potential PDUFA date fo
Slide 10: Glepaglutide has best-in-class potential as a next-generation GLP-2 therapy for patients with SBS
Glepaglutide has best-in-class potential as a next- generation GLP-2 therapy for patients with SBS US FDA has accepted the NDA submission with a PDUFA goal date of December 22, 2024 Significantly reduced weekly PS volume at 24 weeks versus placebo in the EASE-1 trial in SBS1 Expected 10 mg twice-wee
Slide 11: Q1 2024 Profit & Loss
Q1 2024 Profit & Loss DKK million Q1 2024 Q1 2023 P&L reflecting Zealand’s investment in its Revenue 15.1 13.6 differentiated assets targeting obesity Gross profit 10.5 13.6 • Revenue of DKK 15 million is mainly driven by the license and development agreement with Novo Nordisk for Zegalogue®. Resear
Slide 12: Solid cash position allows for investments in R&D
Solid cash position allows for investments in R&D DKK 3.9 billion cash position, including the EIB loan, ensures runway into 2027 3,882 DKK million 3,584 298 350 373 672 1,983 1,450 350 449 -224 -2 2,562 1,184 Cash position Cash flow Other cash Gross Proceeds Cash position EIB loan Cash position Dec
Slide 13: 2024 financial guidance
2024 financial guidance DKK million 2024 2023 Guidance Actual Revenue anticipated from existing and new license and No guidance 343 partnership agreements due to uncertain size and timing Net operating expenses1 1,100 – 1,200 896 Notes: 1. Net operating expenses consist of R&D, S&M, G&A and other op
Slide 14: Significant events and potential catalysts in 2024
Significant events and potential catalysts in 2024 NON-EXHAUSTIVE Q2 2024 H2 2024 Petrelintide Petrelintide Topline results from 16-week Phase 1b MAD trial Initiation of Phase 2b trial Dapiglutide Dapiglutide Topline results from Phase 2a investigator-led trial DREAM Topline results from 13-week Pha
Slide 15: Q&A
Q&A• Q1 2024 presentation May 16, 2024 15